Core Laboratories (NYSE:CLB) Posts Earnings Results, Beats Expectations By $0.01 EPS

Core Laboratories (NYSE:CLB) announced its quarterly earnings data on Wednesday. The oil and gas company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.01, Zacks reports. Core Laboratories had a net margin of 6.04% and a return on equity of 12.22%. The company had revenue of $138.26 million during the quarter, compared to analysts’ expectations of $130.40 million. During the same quarter in the prior year, the company earned $0.22 EPS. The firm’s revenue was up 7.0% on a year-over-year basis. Core Laboratories updated its Q1 2026 guidance to 0.110-0.150 EPS.

Core Laboratories Trading Down 0.0%

Shares of CLB stock traded down $0.01 during mid-day trading on Friday, reaching $18.77. The stock had a trading volume of 44,554 shares, compared to its average volume of 362,028. The firm has a market capitalization of $873.98 million, a PE ratio of 28.02, a price-to-earnings-growth ratio of 17.11 and a beta of 1.09. The stock’s 50-day moving average price is $17.69 and its two-hundred day moving average price is $14.44. The company has a current ratio of 2.37, a quick ratio of 1.76 and a debt-to-equity ratio of 0.41. Core Laboratories has a 52-week low of $9.72 and a 52-week high of $20.36.

Core Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 9th. Shareholders of record on Monday, February 16th will be given a $0.01 dividend. The ex-dividend date is Friday, February 13th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. Core Laboratories’s payout ratio is presently 5.97%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CLB. Disciplined Growth Investors Inc. MN raised its position in Core Laboratories by 9.7% during the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 5,969,860 shares of the oil and gas company’s stock valued at $73,787,000 after purchasing an additional 528,976 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Core Laboratories by 48.1% during the third quarter. Bank of America Corp DE now owns 343,340 shares of the oil and gas company’s stock valued at $4,244,000 after buying an additional 111,527 shares during the period. Hotchkis & Wiley Capital Management LLC increased its stake in shares of Core Laboratories by 22.2% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 559,625 shares of the oil and gas company’s stock valued at $6,917,000 after buying an additional 101,755 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of Core Laboratories by 1,667.2% during the third quarter. BNP Paribas Financial Markets now owns 79,628 shares of the oil and gas company’s stock valued at $984,000 after acquiring an additional 75,122 shares in the last quarter. Finally, Balyasny Asset Management L.P. purchased a new stake in Core Laboratories in the second quarter worth $586,000. Hedge funds and other institutional investors own 97.81% of the company’s stock.

Key Headlines Impacting Core Laboratories

Here are the key news stories impacting Core Laboratories this week:

• Positive Sentiment: Q4 revenue topped estimates — Core reported $138.2M in revenue (up ~7% YoY), beating consensus and showing demand strength, particularly internationally. Core Laboratories Q4 Earnings Beat Estimates, Expenses Increase Y/Y
• Positive Sentiment: Board declared a quarterly dividend ($0.01/share; ex-dividend Feb 13), a small cash-return signal to shareholders. Core Laboratories posts Q4 2025 results and dividend
• Neutral Sentiment: Reported EPS was mixed — management reported $0.21/share (vs. ~$0.20 consensus) but year-over-year EPS is roughly flat/soft versus prior year, showing modest earnings improvement but not a clear acceleration. Core Laboratories (CLB) Beats Q4 Earnings and Revenue Estimates
• Neutral Sentiment: Management highlighted strong international demand but ongoing cost pressures — positive top-line trends are being offset by margin and expense headwinds. Core Laboratories outlines Q1 2026 guidance of $124M–$130M revenue amid strong international demand and cost challenges
• Negative Sentiment: Q1 2026 guidance came in below Street expectations — revenue guided to $124M–$130M (consensus ~ $129.5M) and EPS to $0.11–$0.15 (consensus ~ $0.16), raising near-term growth and margin concerns. Core Laboratories outlines Q1 2026 guidance of $124M–$130M revenue amid strong international demand and cost challenges
• Negative Sentiment: Operating cash flow weakened materially (reported large YoY drop), net income and some cash metrics were mixed — investors worry about cash generation and margin squeeze despite revenue growth. Core Laboratories Inc. (CLB) Stock Falls on Q4 2025 Earnings

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “hold (c)” rating on shares of Core Laboratories in a research report on Monday, December 29th. Four equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $12.50.

Core Laboratories Company Profile

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.